Quintrio
Home

PHARMACEUTICAL PREPARATIONS

Greenwich LifeSciences, Inc.

GLSI

Greenwich LifeSciences Inc a clinical-stage biopharmaceutical company focused on its Phase III clinical trial, Flamingo-01, which is evaluating GLSI-100, an immunotherapy to prevent breast cancer recurrences. GP2 is a 9-amino-acid transmembrane peptide of the HER2/neu protein, a cell surface receptor protein that is expressed in a variety of common cancers, including breast cancers at low (1+), intermediate (2+), and high (3+ or overexpressing) levels.

Last trade $18.31
Day change +$4.55 (+33.07%)
Day range $13.49 – $18.99
Volume 977,534
Market cap $202M

Open XNAS

Fundamentals

Key company ratios and reported financial statements.

Source: Massive.com

Key ratios

Valuation

Market capitalization
$201.97M
Price / earnings
—
Price / book
64.8×
Price / sales
—
EV / sales
—
EV / EBITDA
-8.83×

Profitability

Earnings per share
-$1.48
Return on assets
-244.25%
Return on equity
-695.56%
Dividend yield
0%

Liquidity and leverage

Debt / equity
0×
Current ratio
1.54×
Quick ratio
1.54×
Cash ratio
1.54×

Cash flow

Price / cash flow
—
Price / free cash flow
—
Free cash flow
-$12.49M

Ratios use trailing-twelve-month financials and market data as of Nov 16, 2026.

Financial statements

Income and cash flow amounts are for the period; balance sheets are point-in-time snapshots. Amounts are shown in USD. Latest 8 quarterly or 5 annual periods are displayed when available.

Income statement for GLSI, quarterly periods
Line itemQ2 FY2026 Jun 30, 2026Q1 FY2026 Mar 31, 2026Q4 FY2025 Dec 31, 2025Q3 FY2025 Sep 30, 2025Q2 FY2025 Jun 30, 2025Q1 FY2025 Mar 31, 2025Q4 FY2024 Dec 31, 2024Q3 FY2024 Sep 30, 2024
Revenue$0$0$0$0$0$0$0$0
Cost of revenue$0$0$0$0$0$0$0$0
Gross profit$0$0$0$0$0$0$0$0
Selling, general and administrative$462.93K$518.19K$355.19K$653.07K$352.84K$497.6K$1.02M$437.01K
Research and development$3.56M$5.21M$7.59M$3.52M$3.42M$2.27M$8.69M$2.29M
Total operating expenses$4.02M$5.73M$7.94M$4.17M$3.77M$2.77M$9.71M$2.73M
Operating income-$4.02M-$5.73M-$7.94M-$4.17M-$3.77M-$2.77M-$9.71M-$2.73M
Interest expense$0$0$0$0$0$0$0$0
Income before taxes-$3.95M-$5.66M-$7.92M-$4.15M-$3.75M-$2.74M-$9.67M-$2.67M
Income taxes$0$0$0$0$0$0$0$0
Net income-$3.95M-$5.66M-$7.92M-$4.15M-$3.75M-$2.74M-$9.67M-$2.67M
Net income attributable to common shareholders-$3.95M-$5.66M-$7.92M-$4.15M-$3.75M-$2.74M-$9.67M-$2.67M
EBITDA-$4.02M-$5.73M-$7.94M-$4.17M-$3.77M-$2.77M-$9.71M-$2.73M
Basic earnings per share-$0.27-$0.39-$0.57-$0.30-$0.28-$0.21-$0.74-$0.20
Diluted earnings per share-$0.27-$0.39-$0.57-$0.30-$0.28-$0.21-$0.74-$0.20

Recent news

Company coverage with links to the original publishers.

Publication times in UTC
GlobeNewswire Inc.

Greenwich LifeSciences Announces Acceptance of Abstracts at SABCS 2026

Greenwich LifeSciences announced that two abstracts on its Phase III FLAMINGO-01 clinical trial evaluating GLSI-100 immunotherapy for breast cancer recurrence prevention have been accepted for presentation at the San Antonio Breast Cancer Symposium 2026. The company will present two posters on December 9, 2026, authored by the FLAMINGO-01 Steering Committee.

GlobeNewswire Inc.

Greenwich LifeSciences Provides Update Regarding Form 10-K Filing

Greenwich LifeSciences reported delays in filing its Form 10-K for fiscal year 2025 due to coordination issues between dual auditors regarding accounts payable adjustments related to its Phase III FLAMINGO-01 clinical trial. The company maintains a cash balance of approximately $10.5 million as of March 31, 2026, and reported preliminary positive data from the trial showing a 70-80% reduction in breast cancer recurrence rates in the non-HLA-A*02 patient arm.

GlobeNewswire Inc.

Greenwich LifeSciences Announces Acceptance of Abstract at ASCO 2026

Greenwich LifeSciences announced that an abstract presenting preliminary data from its Phase III FLAMINGO-01 trial of GLSI-100 immunotherapy has been accepted for presentation at the 2026 ASCO Annual Meeting (May 28-June 2). The non-HLA-A*02 open-label arm, now fully enrolled with 250 patients, shows approximately 70-80% reduction in breast cancer recurrence rates after the Primary Immunization Series, consistent with Phase IIb results. The company plans to attend multiple oncology conferences in coming months.

GlobeNewswire Inc.

Greenwich LifeSciences Announces Receipt of Nasdaq Notice Regarding Late Form 10-K Filing

Greenwich LifeSciences received a notification from Nasdaq on April 16, 2026, indicating non-compliance with listing rules due to failure to timely file its Annual Report on Form 10-K for fiscal year 2025. The company's stock continues to trade on Nasdaq Capital Market under ticker GLSI with no immediate effect on listing status. The company is working with auditors to file the report as soon as possible.

GlobeNewswire Inc.

Greenwich LifeSciences Presents FLAMINGO-01 Phase III Trial Open Label Data Published at AACR Meeting 2026

Greenwich LifeSciences presented preliminary immune response data from the Phase III FLAMINGO-01 trial of GLSI-100, an immunotherapy for breast cancer recurrence prevention. The non-HLA-A*02 open label arm (247 patients) showed a statistically significant 4-fold increase in delayed-type-hypersensitivity (DTH) immune reactions from 5.2% at baseline to 20.4% at months 4-6 (p<0.001). Preliminary recurrence rate analysis showed approximately 70-80% reduction in recurrence rates after the primary immunization series, supporting the drug's mechanism of action. Over 1,300 patients have been screened for the trial to date.

Dividends

Declared distributions and recorded event dates. Forecasts are not shown.

Updated daily

No declared upcoming dividend found.

No prior dividend records found.

Stock splits

Historical share-structure events and their execution dates.

Updated daily
Execution dateSplit ratioEvent type
Oct 16, 20142-for-1forward split